Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Sun Pharma to Acquire Odomzo from Novartis 19
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 20
Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 21
Sun Pharma Plans To Acquire Injectable And Oral Business 22
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 23
Venture Financing 24
scPharma Raises USD45.6 Million in Series B Financing 24
Partnerships 26
Sun Pharma Enters into Agreement with National Institute of Virology 26
Sun Pharma Enters into Agreement with International Centre for Genetic Engineering and Biotechnology 27
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 28
Sun Pharma Enters into Co-Development Agreement with International Centre for Genetic Engineering and Biotechnology 29
ICGEB Enters into Partnership with Sun Pharma 30
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 31
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 32
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 33
Mapi Pharma Enters into Agreement with Taro Pharma 34
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 35
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 36
Licensing Agreements 37
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 37
Sun Pharma Enters into Licensing Agreement with Moebius Medical 38
Sun Pharma Enters into Licensing Agreement with SPARC 39
Sun Pharma Enters into Licensing Agreement with Technion to Develop Anti-Cancer Drugs 40
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 41
Sun Pharma Enters into Licensing Agreement with Merck 42
Gilead Sciences Expands Licensing Agreement with Sun Pharma 43
InSite Vision Enters into Licensing Agreement with Senju Pharma for Azithromycin Ophthalmic Solution 44
Suven Life Science Enters Into Licensing Agreement With Taro Pharma To Market Malathion Lotion 45
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 46
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 47
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 48
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 49
Equity Offering 50
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 50
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 51
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 52
Sun Pharma Plans to Raise USD1.97 Billion in Private Placement of Securities 53
Sun Pharma Plans To Raise US$1.5 Billion In Public Offering Of Shares 54
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 55
Debt Offering 57
Sun Pharma Plans to Raise USD1.8 Billion in Private Placement of Debentures 57
Asset Transactions 58
RPG Life Sciences Acquires 7 Prescription Drug Brands from Sun Pharma for USD6 Million 58
Frontida BioPharm Acquires Two Manufacturing Units of Sun Pharma 59
Nostrum Labs to Acquire Manufacturing Unit in Ohio from Sun Pharma 60
Strides Arcolab to Acquire Ranbaxy’s CNS Business from Sun Pharma for USD25 Million 61
Sun Pharma Plans to Divest Ranbaxy’s Ireland Manufacturing Plant 62
Tribute Pharma Acquires US Rights to Fibricor for USD10 Million 63
Emcure Pharma to Acquire Seven Drugs from Sun Pharma and Ranbaxy Labs 64
InSite Vision Sells Royalty Of Besivance To SWK Funding And Bess Royalty For US$16 Million 65
Acquisition 66
Sun Pharma to Acquire 18.75% Stake in Tarsius Pharma for USD3 Million 66
Sun Pharma Acquires Additional 6.35% Stake in Ranbaxy Malaysia for USD0.6 Million 67
Sun Pharma to Acquire 8.3% Stake in Ranbaxy Malaysia 68
Sun Pharma Acquires 15.91% Stake in Krystal Biotech 69
Taro Pharma To Acquire Thallion Pharma for USD2 Million 70
Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 71
Sun Pharma Acquires 85.1% Stake in Biosintez for up to USD60 million 72
Sun Pharma Acquires Ocular Technologies from Auven Therapeutics 73
Sun Pharma May Acquire Controlling Stake in Martindale Pharma 74
Sun Pharma Acquires InSite Vision 75
Taro Pharma Acquires Zalicus Pharma 77
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 78
Sun Pharma Acquires Pharmalucence, Provider of Injectable Pharma Products 81
Sun Pharma To Acquire 28.1% Stake In Zenotech Labs For US$3 Million 82
Sun Pharmaceutical Industries Plans To Acquire Companies In Japan 83
Sun Pharma Completes Acquisition Of Dusa Pharma For US$230 Million 84
Sun Pharma Plans To Acquire Generic Companies 86
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 87
Sun Pharmaceutical Industries Ltd – Key Competitors 88
Sun Pharmaceutical Industries Ltd – Key Employees 89
Sun Pharmaceutical Industries Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Joint Venture 97
Recent Developments 98
Financial Announcements 98
Aug 14, 2018: Sun Pharma reports Q1FY19 results 98
May 25, 2018: Sun Pharma reports Q4 & FY18 results 100
Feb 14, 2018: Sun Pharma reports Q3FY18 results 102
Nov 14, 2017: Sun Pharma reports Q2FY18 results 104
Aug 11, 2017: Sun Pharma reports Q1FY18 results 106
May 26, 2017: Sun Pharma reports Q4 & FY17 results 108
Feb 14, 2017: Sun Pharma reports Q3FY17 results 110
Corporate Communications 112
Mar 23, 2018: FDEC First Year Report of Malaria Elimination Demonstration Project (MEDP) 112
Jul 12, 2017: Sun Pharmaceutical Industries Announces Appointment of Mr. Kalyansundaram Subramanian as the Director 113
Legal and Regulatory 114
Jun 12, 2018: Sun Pharma receives EIR for Halol facility 114
Feb 23, 2018: Sun Pharmaceutical Industries: Update on US FDA Halol Inspection 115
Jul 07, 2017: SUN Pharma: Intimation of settlement in re Modajmnil Antitrust Litigation matter 116
Mar 14, 2017: Sun Pharma Provides Update on Mohali Facility 117
Mar 14, 2017: Sun Pharmaceutical Industries Provides Update on Mohali Facility 118
Product News 119
Aug 29, 2018: Sun Pharma launches Volini Maxx, India’s Strongest Pain Relief Spray 119
Appendix 120
Methodology 120
About GlobalData 120
Contact Us 120
Disclaimer 120
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Sun Pharma to Acquire Odomzo from Novartis 19
Sun Pharma Acquires 14 Brands from Novartis for USD293 Million 20
Sun Pharma Acquires Opiates Business in Australia from GlaxoSmithKline 21
Sun Pharma Plans To Acquire Injectable And Oral Business 22
InSite Vision Regains North American Development Rights To AzaSite Xtra From Inspire Pharma 23
scPharma Raises USD45.6 Million in Series B Financing 24
Sun Pharma Enters into Agreement with National Institute of Virology 26
Sun Pharma Enters into Agreement with International Centre for Genetic Engineering and Biotechnology 27
Sun Pharma Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 28
Sun Pharma Enters into Co-Development Agreement with International Centre for Genetic Engineering and Biotechnology 29
ICGEB Enters into Partnership with Sun Pharma 30
Sun Pharma Enters into Co-Marketing Agreement with AstraZenceca Pharma for Dapagliflozin 31
Sun Pharma Enters into Research Agreement with Weizmann Institute of Science and Health Research Institute of Santiago de Compostela 32
Sun Pharma Enters into Distribution Agreement with Astrazeneca Pharma 33
Mapi Pharma Enters into Agreement with Taro Pharma 34
Sun Pharma Forms Joint Venture With Intrexon To Develop Therapeutics For Ocular Diseases 35
Daiichi Sankyo Enters Into Co-Marketing Agreement With Terapia Ranbaxy For Sevikar 36
Taro Pharma Enters into Licensing Agreement with Crescita Therapeutics 37
Sun Pharma Enters into Licensing Agreement with Moebius Medical 38
Sun Pharma Enters into Licensing Agreement with SPARC 39
Sun Pharma Enters into Licensing Agreement with Technion to Develop Anti-Cancer Drugs 40
InSite Vision Enters into Licensing Agreement with Nicox for AzaSite, AzaSite Xtr and BromSite 41
Sun Pharma Enters into Licensing Agreement with Merck 42
Gilead Sciences Expands Licensing Agreement with Sun Pharma 43
InSite Vision Enters into Licensing Agreement with Senju Pharma for Azithromycin Ophthalmic Solution 44
Suven Life Science Enters Into Licensing Agreement With Taro Pharma To Market Malathion Lotion 45
Almirall Enters into Licensing Agreement with Sun Pharma for Tildrakizumab 46
Sun Pharma Advanced Research Enters Into Licensing Agreement With Sun Pharma 47
Ranbaxy Pharma Enters Into Licensing Agreement With Alembic Pharma For Desvenlafaxine Base Extended-Release Tablets 48
InSite Vision Amends Licensing Agreement With Inspire Pharma For AzaSite 49
Sun Pharma Advanced Plans to Raise Additional Funds in Rights Offering of Shares 50
Sun Pharma Advanced Research Company to Raise USD39 Million in Rights Offering of Shares 51
Daiichi Sankyo Raises USD3.6 Billion in Public Offering of Shares of Sun Pharma 52
Sun Pharma Plans to Raise USD1.97 Billion in Private Placement of Securities 53
Sun Pharma Plans To Raise US$1.5 Billion In Public Offering Of Shares 54
Sun Pharma Advanced Research Completes Rights Issue Of Shares For US$36 Million 55
Sun Pharma Plans to Raise USD1.8 Billion in Private Placement of Debentures 57
RPG Life Sciences Acquires 7 Prescription Drug Brands from Sun Pharma for USD6 Million 58
Frontida BioPharm Acquires Two Manufacturing Units of Sun Pharma 59
Nostrum Labs to Acquire Manufacturing Unit in Ohio from Sun Pharma 60
Strides Arcolab to Acquire Ranbaxy's CNS Business from Sun Pharma for USD25 Million 61
Sun Pharma Plans to Divest Ranbaxy’s Ireland Manufacturing Plant 62
Tribute Pharma Acquires US Rights to Fibricor for USD10 Million 63
Emcure Pharma to Acquire Seven Drugs from Sun Pharma and Ranbaxy Labs 64
InSite Vision Sells Royalty Of Besivance To SWK Funding And Bess Royalty For US$16 Million 65
Sun Pharma to Acquire 18.75% Stake in Tarsius Pharma for USD3 Million 66
Sun Pharma Acquires Additional 6.35% Stake in Ranbaxy Malaysia for USD0.6 Million 67
Sun Pharma to Acquire 8.3% Stake in Ranbaxy Malaysia 68
Sun Pharma Acquires 15.91% Stake in Krystal Biotech 69
Taro Pharma To Acquire Thallion Pharma for USD2 Million 70
Sun Pharma Acquires 14.58% Stake in scPharma for USD13 Million 71
Sun Pharma Acquires 85.1% Stake in Biosintez for up to USD60 million 72
Sun Pharma Acquires Ocular Technologies from Auven Therapeutics 73
Sun Pharma May Acquire Controlling Stake in Martindale Pharma 74
Sun Pharma Acquires InSite Vision 75
Taro Pharma Acquires Zalicus Pharma 77
Sun Pharma Acquires Ranbaxy Labs for USD4 Billion 78
Sun Pharma Acquires Pharmalucence, Provider of Injectable Pharma Products 81
Sun Pharma To Acquire 28.1% Stake In Zenotech Labs For US$3 Million 82
Sun Pharmaceutical Industries Plans To Acquire Companies In Japan 83
Sun Pharma Completes Acquisition Of Dusa Pharma For US$230 Million 84
Sun Pharma Plans To Acquire Generic Companies 86
Sun Pharma Mulls Acquisition Of Stada Arzneimittel 87
Sun Pharmaceutical Industries Ltd, Key Competitors 88
Sun Pharmaceutical Industries Ltd, Key Employees 89
Sun Pharmaceutical Industries Ltd, Subsidiaries 90
Sun Pharmaceutical Industries Ltd, Joint Venture 97
List of Figures
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Sun Pharmaceutical Industries Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Sun Pharmaceutical Industries Ltd, Medical Devices Deals, 2012 to YTD 2018 13